Stocks · Health care · Pharmaceutical Preparations

Sarepta Therapeutics, Inc.

SRPT Clue Score48
United States Fiscal year ends December CIK 0000873303 Results filed 5 Nov 2026

What the insiders did No buying or selling

By person

16 insiders · 0 transactions
13.5×

Douglas S. Ingram holds 13.5 times base salary in stock. $15.82M of shares against $1.17M in salary for 2025.

Salary from the company's own proxy. The shares are what Douglas S. Ingram last reported holding, valued at $17.02, the price Common Stock was last bought or sold at on the open market here, on 12 Mar 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Richard Barry
Director
—
—
—
2,983,542
$50.78M
+1.8%
Douglas S Ingram
Chief Executive Officer
—
—
—
929,391
$15.82M
+138.1%
Michael Severino
Chief Executive Officer
—
—
—
756,104
$12.87M
—
M Kathleen Behrens
Director
—
—
—
214,357
$3.65M
+12.2%
Louise Rodino-Klapac
President, R&D and Tech Ops
—
—
—
203,900
$3.47M
+181.6%
Ian Michael Estepan
Chief Operating Officer
—
—
—
177,184
$3.02M
+422.0%
Ryan Ho-Yan Wong
Chief Financial Officer
—
—
—
121,792
$2.07M
+589.8%
Cristin Rothfuss
EVP, General Counsel
—
—
—
115,519
$1.97M
+738.4%
Claude Nicaise
Director
—
—
—
48,407
$823.89K
+166.4%
Hans Lennart Rudolf Wigzell
Director
—
—
—
42,098
$716.51K
+84.3%
Dallan Murray
Chief Customer Officer
—
—
—
38,202
$650.20K
+71.9%
Bilal Arif
Chief Tech Ops Officer
—
—
—
32,500
$553.15K
+85.6%
Michael Andrew Chambers
Director
—
—
—
27,535
$468.65K
+232.7%
Kathryn Jean Boor
Director
—
—
—
25,138
$427.85K
+234.5%
Deirdre P Connelly
Director
—
—
—
22,100
$376.14K
+677.6%
Stephen Mayo
Director
—
—
—
18,640
$317.25K
+181.5%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.